Home A Different Class of ADT Control CV Risk Economic Burden of CVD Events Disease-Related Symptoms Delay Disease Progression Patient Satisfaction Support & Resources Dosing & Administration Firmagon Licence Prescribing Information

FIRMAGON^® treating beyond the prostate

Learn more about how Firmagon can help benefit patients with CVD risk^1-6

Learn More...

CVD is the leading cause of death in prostate cancer patients, after prostate cancer itself^7,8

Up to 30% of prostate cancer patients are likely to be at high risk of a CV event²

LHRH agonists are associated with a significantly increased risk of CV events vs. no treatment⁹

Compared with no treatment, LHRH agonists (including leuprorelin and goserelin) increase the risk of ⁹

Diabetes
(HR: 1.44, 95% CI: 1.34–1.55, p<0.001)

Coronary heart disease
(HR: 1.16, 95% CI: 1.10–1.21, p<0.001)

Myocardial infarction
(HR: 1.11, 95% CI: 1.01–1.21, p=0.03)

Sudden cardiac death
(HR: 1.16, 95% CI: 1.05–1.27, p=0.004)

FIRMAGON^® significantly lowers the risk of CV events vs. LHRH agonists^1-6

In a retrospective pooled analysis from six Phase III, prospective, RCTS of prostate cancer patients (N=2,328)
what do you think the number needed to treat is for FIRMAGON^®?

NTT=12²

And in a real-world study in the UK, what do you think the number needed to treat is for FIRMAGON^®?

NTT=9^1†

UK Primary Care database of patients with prostate cancer (population-based cohort study)¹

(n=9,081, aged ≥40 years)

More patients prescribed FIRMAGON^® had pre-existing CVD at baseline vs. patients on LHRH agonists^*

6.9% estimated relative risk of CV event with FIRMAGON^® vs.17.7% with LHRH agonists>

(RR 0.39) (95% CI 0.191-0.799, p=0.01)

* LHRH agonists refers to pooled data of patients receiving leuprorelin, goserelin and triptorelin.
‍† Calculated by Ferring using relative and absolute risk reduction.

▲ SECTION NAVIGATION ▲

Cardio Vascular Disease

Risk of CV events

Lower the risk

Real-world study

References

References
1. Davey P and Kirby M. J Urol 2020;203(4S):e250–e251.
2. Albertsen PC, et al. Eur Urol 2014;65:565–573.
3. Perrone V, et al. Ther Clin Risk Manag 2020;16:393-401.
4. Cone EB, et al. J Clin Oncol 2020;38:6 Suppl 34.
5. Margel D, et al. J Urol 2019; 202(6): 1199-1208.
6. Zhang K W, et al. J Urol 2021; 206(3): 613-622.
7. Plummer C, et al. Trends Urol Men’s Health 2017;13–18.
8. Chowdhury S, et al. BJU Int 2013;112(2):182-9.
9. Keating NL, et al. J Clin Oncol 2006;24:4448–4456.

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.

FIRMAGON® treating beyond the prostate

Learn more about how Firmagon can help benefit patients with CVD risk1-6

CVD is the leading cause of death in prostate cancer patients, after prostate cancer itself7,8

LHRH agonists are associated with a significantly increased risk of CV events vs. no treatment9

FIRMAGON® significantly lowers the risk of CV events vs. LHRH agonists1-6

NTT=122

And in a real-world study in the UK, what do you think the number needed to treat is for FIRMAGON®?

NTT=91†